6.29
1.94%
+0.12
Dopo l'orario di chiusura:
6.39
0.10
+1.59%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché OCUL Giù?
Forum
Previsione
Ocular Therapeutix Inc Borsa (OCUL) Ultime notizie
Diabetic Retinopathy Pipeline Analysis, 2024 Updates | Latest FDA, EMA, and PMDA Approvals - openPR
openPR
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Sold by Ieq Capital LLC - Defense World
Defense World
Ocular Therapeutix: 2Q Earnings Snapshot - Yahoo News UK
Yahoo News UK
Ocular Therapeutix: 2Q Earnings Snapshot - Yahoo News UK
Yahoo News UK
When the Price of (OCUL) Talks, People Listen - Stock Traders Daily
Stock Traders Daily
Read This Before Selling Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares - Yahoo New Zealand News
Yahoo New Zealand News
Ocular Therapeutix (OCUL) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Canada Shine On
Yahoo Canada Shine On
Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Lifestyle UK
Yahoo Lifestyle UK
Loss-Making Ocular Therapeutix, Inc. (NASDAQ:OCUL) Expected To Breakeven - Yahoo New Zealand News
Yahoo New Zealand News
Ocular Therapeutix (NASDAQ:OCUL) Trading 7.8% Higher - MarketBeat
MarketBeat
Q2 2024 EPS Estimates for Ocular Therapeutix, Inc. Decreased by HC Wainwright (NASDAQ:OCUL) - MarketBeat
MarketBeat
Ocular Therapeutix (NASDAQ:OCUL) Trading Down 7% - Defense World
Defense World
Analysts Set Ocular Therapeutix, Inc. (NASDAQ:OCUL) Target Price at $15.17 - MarketBeat
MarketBeat
Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Lifestyle UK
Yahoo Lifestyle UK
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Defense World
Ocular Therapeutix (NASDAQ:OCUL) Trading Down 7% - MarketBeat
MarketBeat
Ocular Therapeutix (NASDAQ:OCUL) shareholders have endured a 21% loss from investing in the stock five years ago - Yahoo Movies UK
Yahoo Movies UK
Ocular Therapeutix (NASDAQ:OCUL) Price Target Cut to $22.00 by Analysts at JMP Securities - Defense World
Defense World
HC Wainwright Lowers Ocular Therapeutix (NASDAQ:OCUL) Price Target to $14.00 - Defense World
Defense World
Ocular Therapeutix (NASDAQ:OCUL) Trading Down 7% - MarketBeat
MarketBeat
Implied Volatility Surging for Ocular Therapeutix (OCUL) Stock Options - Yahoo News UK
Yahoo News UK
Ocular Therapeutix (NASDAQ:OCUL) Price Target Cut to $14.00 - MarketBeat
MarketBeat
Ocular Therapeutix (NASDAQ:OCUL) Price Target Cut to $14.00 - MarketBeat
MarketBeat
Ocular Therapeutix: Q1 Earnings Snapshot - Houston Chronicle
Houston Chronicle
Ocular Therapeutix Inc Reports First Quarter 2024 Earnings - Yahoo Finance
Yahoo Finance
Ocular Therapeutix Inc earnings missed by $0.31, revenue fell short of estimates - Investing.com India
Investing.com India
Ocular Therapeutix: Q1 Earnings Snapshot - Houston Chronicle
Houston Chronicle
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
GlobeNewswire
Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences - Investing.com India
Investing.com India
Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences - GlobeNewswire
GlobeNewswire
Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences - Yahoo Finance
Yahoo Finance
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
GlobeNewswire
Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024 - GlobeNewswire
GlobeNewswire
Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024
GlobeNewswire Inc.
Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024 - GlobeNewswire
GlobeNewswire
Ocular Therapeutix (NASDAQ:OCUL) Trading 10% Higher - MarketBeat
MarketBeat
Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024
GlobeNewswire Inc.
Wall Street Breakfast: The Week Ahead
Seeking Alpha
2 Small-Cap Growth Stocks With Room to Run
The Motley Fool
Baird sees weakness in Ocular shares as "overdone" (NASDAQ:OCUL) - Seeking Alpha
Seeking Alpha
Ocular reports promising results for diabetic retinopathy treatment - Investing.com Nigeria
Investing.com Nigeria
Ocular Therapeutix (NASDAQ:OCUL) Shares Gap Up to $7.79 - MarketBeat
MarketBeat
The Analyst Verdict: Ocular Therapeutix In The Eyes Of 8 Experts
Benzinga
The Analyst Verdict: Ocular Therapeutix In The Eyes Of 8 Experts - Ocular Therapeutix (NASDAQ:OCUL) - Benzinga
Benzinga
Ocular Therapeutix appoints new CEO amid leadership shift - Investing.com
Investing.com
Sustained Release Ocular Drug Delivery Systems Market Analysis to 2030 | Allergan, Icon Bioscience, Ocular ... - Currency News Centre
Currency News Centre
Down -17.88% in 4 Weeks, Here's Why Ocular Therapeutix (OCUL) Looks Ripe for a Turnaround
Zacks Investment Research
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics
GlobeNewswire Inc.
Down -17.88% in 4 Weeks, Here's Why Ocular Therapeutix (OCUL) Looks Ripe for a Turnaround - Yahoo Finance
Yahoo Finance
Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
GlobeNewswire Inc.
Capitalizzazione:
|
Volume (24 ore):